Medical Center Dea Medicals EOOD
- Address
- Ulitsa Morits Levi 2, 2500 Kyustendil, Bulgaria
Medical Center Dea Medicals EOOD - Cardiovascular Research Center
Medical Center Dea Medicals EOOD is a specialized cardiovascular research facility dedicated to advancing the prevention and treatment of heart disease through participation in innovative clinical trials. The center demonstrates particular expertise in evaluating novel therapeutic interventions for patients with heart failure and atherosclerotic cardiovascular disease, contributing to the development of next-generation treatments that address both symptomatic management and long-term cardiovascular risk reduction.
- Heart failure treatment optimization studies, including dose-finding investigations and novel pharmacological interventions in patients with reduced ejection fraction
- Secondary prevention trials targeting major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease
- Primary prevention strategies utilizing innovative lipid-lowering therapies to reduce cardiovascular risk in high-risk patient populations
The research center's comprehensive approach spans the entire spectrum of cardiovascular care, from primary prevention in high-risk individuals to advanced heart failure management. Their clinical trial portfolio includes investigations of inclisiran, a cutting-edge therapy for cholesterol management, and experimental treatments targeting NT-proBNP reduction in heart failure patients. This broad expertise positions Medical Center Dea Medicals EOOD as a significant contributor to evidence-based cardiovascular medicine and the development of therapies that may fundamentally change how we prevent and treat cardiovascular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1AstraZeneca AB3active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Dea Medicals EOOD
lock Showing 1 of 24 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of XXB750 in Heart Failure Patients with LVEF < 50% on Standard Care Including ACEI/ARB or Sacubitril/Valsartan | Novartis Pharma AG | Phase II | Not Recruiting | Mar 2024 | Nov 2024 |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 3 | Unknown | 2024-10-18 | 2025-10-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.